U.S. markets close in 46 minutes

The Cooper Companies, Inc. (COO)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
346.19-10.26 (-2.88%)
As of 3:14PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close356.45
Open352.12
Bid348.20 x 800
Ask348.72 x 800
Day's Range345.64 - 353.70
52 Week Range236.68 - 365.68
Volume95,731
Avg. Volume267,295
Market Cap18.466B
Beta (5Y Monthly)0.82
PE Ratio (TTM)61.84
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.06 (0.02%)
Ex-Dividend DateJul 22, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-24% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    CooperSurgical and NYU Langone Fertility Center Announce Study Data Showing Significant Increase in Ongoing Pregnancy and Live Birth Rates with Genetic Test Using Artificial Intelligence (PGTai 2.0 platform) for Patients Undergoing IVF

    Data from NYU Langone Fertility Center Study Presented at American Society of Reproductive Medicine Annual MeetingTRUMBULL, Conn. and NEW YORK, Oct. 19, 2020 (GLOBE NEWSWIRE) -- CooperSurgical and NYU Langone Fertility Center (NYULFC), part of The Prelude Network, announced today independent study results demonstrating increased ongoing pregnancy and live birth rates associated with the use of CooperSurgical's PGTai 2.0 technology to screen embryos for in vitro fertilization (IVF).1 This single-center study was conducted by NYULFC; and results were presented today at the American Society of Reproductive Medicine (ASRM) Virtual Scientific Congress.Preimplantation Genetic Testing for aneuploidy (PGT-A) is performed on embryos produced through IVF; it provides genetic information to help identify embryos that are more likely to result in a successful pregnancy. PGTai 2.0 is an advancement in PGT-A testing that utilizes artificial intelligence to increase objectivity of this screening process.“This research moves us an important step closer to our goal of increased live births, improved pregnancy outcomes and further reduction of multiples in pregnancy through greater confidence in single embryo transfer,” said James A. Grifo, M.D., Ph.D., Director, NYU Langone Fertility Center.An estimated 48.5 million couples – approximately 15% of couples -- are affected by infertility worldwide.2 80,000 babies were born with IVF in 2017 in the United States3 and more than one million babies were born in the period 1987 to 2015 in the United States as a result of IVF.4  “The study is a demonstration of CooperSurgical’s commitment to developing the most advanced technology in the field of genetic testing to advance reproductive medicine and help families,” said Tony Gordon, Vice President of Business Development, CooperGenomics. “By applying artificial intelligence in the PGTaism2.0 technology, we leverage mathematical algorithms derived from real-world data to achieve objective embryo assessment.”About the Study The retrospective study included data from more than 700 patients in the NYU Langone Fertility Center in New York, N.Y.The study compared results from three next generation sequencing (NGS) genetic tests: Standard NGS, NGS with first generation artificial intelligence (PGTai 1.0 Technology Platform) and NGS with second generation artificial intelligence (PGTai 2.0 Technology Platform). The ongoing pregnancy and live birth rates significantly increased by a relative 13 percent in the PGTai 2.0 group as compared to subjective and prior methodologies.Study results also suggest that the increase in ongoing pregnancy and live births may be linked to improvements in several preceding IVF outcomes (implantation rates, clinical pregnancy rates and pregnancy loss).About NYU Langone Fertility Center NYU Langone Fertility Center provides world class science and exceptional clinical care to patients seeking fertility treatment. For over 25 years, the Fertility Center has been on a mission to help educate women and men about their reproductive health, and to deliver data-driven guidance at each step in the fertility care process. NYU Langone Fertility Center is proud to serve all families with compassionate, individualized, and cost-effective treatment options.The Fertility Center has helped thousands of patients realize their dreams of having a family, and its dedicated physicians have over 125 years of collective experience performing IVF. Each physician is certified in Reproductive Endocrinology and Infertility (REI) with the American Board of Obstetrics and Gynecology, and many of its physicians also hold Professor or Assistant Professor positions within the Department of Obstetrics and Gynecology at NYU Langone Health. While they are physicians first and foremost, the Fertility Center’s physicians are also active participants in clinical research to advance the safety, success, and affordability of fertility care.About CooperSurgical CooperSurgical is a leader in delivering innovative assisted reproductive technology and genomic solutions that enhance the work of ART professionals to the benefit of families. Its experience working with embryologists and IVF professionals across the globe, and offering a portfolio of products for the entire ART process, means that it can help meet the exacting needs of ART clinics.CooperSurgical is a wholly-owned subsidiary of CooperCompanies (NYSE: COO). CooperSurgical headquartered in Trumbull, CT, produces and markets a wide array of products and services for use by women’s health care clinicians. More information can be found at fertility.coopersurgical.com.About CooperCompanies CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.Contacts:CooperSurgical Caren Begun Green Room Communications 201-396-8551 caren@greenroompr.comNYU Langone Fertility Center Mia Humphreys Krupp Kommunications 239-297-6592 Mhumphreys@kruppnyc.com________________________________ 1 Buldo-Licciardi J, Large M, McCulloh D, McCaffrey C, Grifo J. Second generation artificial intelligence technology for preimplantation genetic testing (PRT) improves pregnancy outcomes in single thawed euploid embryo transfer cycles (STEET). Presented at American Society for Reproductive Medicine on October 19, 2020. Available at: https://asrm.confex.com/asrm/2020/meetingapp.cgi/Paper/8645. Accessed October 13, 2020. 2 Agarwal A, Mulgund A, Hamada A, Chyatte MR. A unique view on male infertility around the globe. Reprod Biol Endocrinol. 2015;13:37. Published 2015 Apr 26. doi:10.1186/s12958-015-0032-1. Accessed October 13, 2020. 3 Centers for Disease Control and Prevention. ART Success Rates. Available at: https://www.cdc.gov/art/artdata/index.html. Accessed October 13, 2020. 4 Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. 2015 Assisted Reproductive Technology National Summary Report. Available at: https://www.cdc.gov/art/pdf/2015-report/ART-2015-National-Summary-Report.pdf. Accessed October 13, 2020.

  • CooperVision Presents Six-Year Data from MiSight® 1 Day Study; 23% of Eyes Showed No Additional Myopia Progression After Fitting
    PR Newswire

    CooperVision Presents Six-Year Data from MiSight® 1 Day Study; 23% of Eyes Showed No Additional Myopia Progression After Fitting

    CooperVision is reporting the latest findings from its landmark MiSight® 1 day clinical study, providing new insights about myopia management and the proven efficacy of the specially designed contact lens. Among many powerful outcomes are that nearly one in four children's eyes originally fit with MiSight® 1 day remain stable for myopia after six years.1

  • GlobeNewswire

    CooperCompanies and Divisions Named One of Fortune’s Best Large Workplaces in Manufacturing and Production

    CooperCompanies, CooperVision and CooperSurgical All Recognized by Fortune MagazineSAN RAMON, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO) announced today that the company, along with its CooperVision and CooperSurgical divisions has been named one of Fortune's Best Large Workplaces in Manufacturing and Production. “Being included on Fortune’s Best Large Workplaces in Manufacturing and Production List is a testament to our outstanding employees,” said President and CEO Albert White. “For both CooperVision and CooperSurgical, our manufacturing and production teams are the backbone of the businesses, ensuring we produce, maintain and deliver our products around the globe.  In many ways, this award highlights the team effort across the organization from the products that our R+D teams invent and study, our M+A team’s purchase, our marketing teams promote, and our sales representatives sell.”To determine the companies selected for this list, Fortune research partner Great Place to Work® analyzed responses from more than 160,000 employees at Great Place to Work-Certified™ organizations in the Manufacturing & Production industry. Employees responded to more than 60 survey questions anonymously rating their employers, assessing workplace culture, employee experience, and leadership behaviors.According to White, being on this list is indicative of the emphasis the company puts on cooperation: “Partnership is a key element of our DNA – not just with our customers but also with our employees. During these difficult times we have heard from so many of our customers that they feel like we are an integral part of their team. For example, over the past months we had customers calling desperate for product and our teams worked night and day to get them what they needed. Our team knows that at the other end of every request is a woman making an important decision about her health or a person who needs to see clearly.”About Great Place to Work Great Place to Work® is a global authority on workplace culture. Since 1992, it has surveyed more than 100 million employees around the world and used those insights to define what makes a great workplace: trust. Great Place to Work helps organizations quantify their cultures and produce better business results by creating a high-trust work experience for all employees. Their benchmark data is used to recognize Great Place to Work-Certified companies and the Best Workplaces™ in the United States and more than 60 countries, including the 100 Best Companies to Work For® and World’s Best lists published annually in Fortune. To learn more, visit greatplacetowork.com.About CooperCompanies CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.Contact: Kim Duncan Vice President, Investor Relations and Risk Management 925-460-3663 ir@cooperco.com